ราคาของ InnoPharmax Inc. (4172) คืออะไร

ราคาของ InnoPharmax Inc. (4172) คือ $0.35614911

หมวกตลาดของ InnoPharmax Inc. คืออะไร (4172)

ฝาครอบตลาดของ InnoPharmax Inc. (4172) คือ $41.95M

รายได้ของ InnoPharmax Inc. (4172)

InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.

ปี	รายได้	เปลี่ยน
ข้อมูลไม่เพียงพอสำหรับวันที่ที่ให้ไว้

ปี

รายได้

เปลี่ยน

ข้อมูลไม่เพียงพอสำหรับวันที่ที่ให้ไว้

บริษัท	รายได้	ความแตกต่างของรายได้	ประเทศ
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$6.61B	-	IN

บริษัท

รายได้

ความแตกต่างของรายได้

ประเทศ